ACIU vs. MRVI, ELVN, PAHC, ZYME, ABCL, REPL, COLL, RCKT, EOLS, and PHVS
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
AC Immune vs.
AC Immune (NASDAQ:ACIU) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
AC Immune currently has a consensus target price of $12.00, suggesting a potential upside of 354.55%. Maravai LifeSciences has a consensus target price of $10.28, suggesting a potential upside of 150.15%. Given AC Immune's stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Maravai LifeSciences.
51.4% of AC Immune shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 0.6% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
AC Immune has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat AC Immune's return on equity.
AC Immune received 196 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 62.63% of users gave Maravai LifeSciences an outperform vote while only 62.47% of users gave AC Immune an outperform vote.
AC Immune has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500.
AC Immune has higher earnings, but lower revenue than Maravai LifeSciences. AC Immune is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Maravai LifeSciences had 3 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Maravai LifeSciences and 1 mentions for AC Immune. AC Immune's average media sentiment score of 0.59 beat Maravai LifeSciences' score of 0.27 indicating that AC Immune is being referred to more favorably in the media.
Summary
AC Immune beats Maravai LifeSciences on 11 of the 18 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
This page (NASDAQ:ACIU) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ACIU Stock Alerts